Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment – Renal and Urology News
|
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Renal and Urology News The CheckMate-214 trial demonstrated that combined immunotherapy with the checkpoint inhibitors nivolumab and ipilimumab results in superior outcomes—including significantly better objective response rate (ORR), progression-free survival (PFS), and … |
